Description: Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Home Page: www.thirdharmonicbio.com
THRD Technical Analysis
1700 Montgomery Street
San Francisco,
CA
94111
United States
Phone:
(209) 727-2457
Officers
| Name | Title |
|---|---|
| Ms. Natalie C. Holles | CEO & Director |
| Ms. Julie Person | Chief Administrative Officer |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Mr. Christopher Murphy | Chief Financial & Business Officer |
| Ms. Jennifer Dittman | Chief Operating Officer |
| Dr. Christopher J. Dinsmore Ph.D. | Chief Scientific Officer |
| Mr. Steven P. Sweeney | Senior Vice President of Development Operations |
| Mr. Dennis Dean Ph.D. | Chief Non-Clinical Development Officer |
| Ommer Chohan | Treasurer & Secretary |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7192 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-09-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 51 |